Combined Osteopontin Blockade and Type 2 Classical Dendritic Cell Vaccination as Effective Synergetic Therapy for Conjunctival Melanoma

Jennifer Peil, Christian Vossen, Felix Bock, Thomas Clahsen, Petra Schiller, Ludwig M. Heindl, Jacobus J. Bosch, F. Thomas Wunderlich, Claus Cursiefen, Simona L. Schlereth
{"title":"Combined Osteopontin Blockade and Type 2 Classical Dendritic Cell Vaccination as Effective Synergetic Therapy for Conjunctival Melanoma","authors":"Jennifer Peil, Christian Vossen, Felix Bock, Thomas Clahsen, Petra Schiller, Ludwig M. Heindl, Jacobus J. Bosch, F. Thomas Wunderlich, Claus Cursiefen, Simona L. Schlereth","doi":"10.4049/jimmunol.2300063","DOIUrl":null,"url":null,"abstract":"<jats:title>Abstract</jats:title> Angiogenesis and immune protection are essential at the onset of tumorigenesis. Angiogenesis serves to nourish the tumor, and prevention of immune defenses, for example, by dendritic cells (DCs), allows tumor growth. In this study, we investigated whether there are factors with dual functions that are both angiogenic and immunomodulatory and represent a therapeutic target. We analyzed 1) innate immune responses intratumorally and in draining lymph nodes and 2) angiogenic factors in conjunctival melanoma (CM), a potentially lethal malignant tumor at the ocular surface whose immune and vascular responses are largely unknown. For this purpose, an HGF-Cdk4R24C model in immunocompetent C57BL/6 mice was used and revealed that CD103− type 2 classical DC (cDC2s) were the most abundant DC subtype in healthy conjunctiva, whereas in CM, CD103− cDC2s, CD103+ type 1 cDCs, monocyte-derived DCs, and plasmacytoid DCs were significantly increased. In our analysis of angiogenic factors in CM, the examination of 53 angiogenesis-related factors that might interact with DCs identified osteopontin (OPN) as a major tumor-derived protein that interacts with DCs. Consistent with these findings, 3) a dual therapeutic strategy that inhibited tumor cell function by an OPN blocking Ab while enhancing the immune response by cDC2 vaccination resulted in 35% failure of tumor development. Moreover, tumor progression, monocyte-derived DC infiltration, and intratumoral angiogenesis were significantly reduced, whereas survival and CD8+ T cell infiltration were increased in treated mice compared with the control group. Therefore, we identified OPN blockade in combination with cDC2 vaccination as a potential future therapeutic intervention for early stages of CM by combining antiangiogenic and host immune stimulating effects.","PeriodicalId":22698,"journal":{"name":"The Journal of Immunology","volume":"128 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4049/jimmunol.2300063","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract Angiogenesis and immune protection are essential at the onset of tumorigenesis. Angiogenesis serves to nourish the tumor, and prevention of immune defenses, for example, by dendritic cells (DCs), allows tumor growth. In this study, we investigated whether there are factors with dual functions that are both angiogenic and immunomodulatory and represent a therapeutic target. We analyzed 1) innate immune responses intratumorally and in draining lymph nodes and 2) angiogenic factors in conjunctival melanoma (CM), a potentially lethal malignant tumor at the ocular surface whose immune and vascular responses are largely unknown. For this purpose, an HGF-Cdk4R24C model in immunocompetent C57BL/6 mice was used and revealed that CD103− type 2 classical DC (cDC2s) were the most abundant DC subtype in healthy conjunctiva, whereas in CM, CD103− cDC2s, CD103+ type 1 cDCs, monocyte-derived DCs, and plasmacytoid DCs were significantly increased. In our analysis of angiogenic factors in CM, the examination of 53 angiogenesis-related factors that might interact with DCs identified osteopontin (OPN) as a major tumor-derived protein that interacts with DCs. Consistent with these findings, 3) a dual therapeutic strategy that inhibited tumor cell function by an OPN blocking Ab while enhancing the immune response by cDC2 vaccination resulted in 35% failure of tumor development. Moreover, tumor progression, monocyte-derived DC infiltration, and intratumoral angiogenesis were significantly reduced, whereas survival and CD8+ T cell infiltration were increased in treated mice compared with the control group. Therefore, we identified OPN blockade in combination with cDC2 vaccination as a potential future therapeutic intervention for early stages of CM by combining antiangiogenic and host immune stimulating effects.
联合使用骨蛋白阻断剂和 2 型经典树突状细胞疫苗是治疗结膜黑色素瘤的有效协同疗法
摘要 血管生成和免疫保护在肿瘤发生之初至关重要。血管生成为肿瘤提供营养,而树突状细胞(DCs)等免疫防御机制的阻碍则会使肿瘤生长。在这项研究中,我们探讨了是否存在具有双重功能的因子,它们既能促进血管生成,又能调节免疫,并成为治疗靶点。我们分析了:1)瘤内和引流淋巴结的先天性免疫反应;2)结膜黑色素瘤(CM)的血管生成因子,这是一种潜在的致命性眼表恶性肿瘤,其免疫和血管反应在很大程度上是未知的。为此,我们在免疫功能正常的 C57BL/6 小鼠中使用了 HGF-Cdk4R24C 模型,结果发现 CD103- 2 型经典 DC(cDC2s)是健康结膜中最丰富的 DC 亚型,而在 CM 中,CD103- cDC2s、CD103+ 1 型 cDCs、单核细胞衍生 DCs 和类浆细胞 DCs 显著增加。在我们对 CM 中血管生成因子的分析中,对 53 种可能与 DCs 相互作用的血管生成相关因子的研究发现,骨生成素(OPN)是一种与 DCs 相互作用的主要肿瘤衍生蛋白。与这些研究结果相一致,3) 通过 OPN 阻断抗体抑制肿瘤细胞功能,同时通过接种 cDC2 疫苗增强免疫反应的双重治疗策略导致 35% 的肿瘤发展失败。此外,与对照组相比,治疗组小鼠的肿瘤进展、单核细胞衍生 DC 浸润和瘤内血管生成明显减少,而存活率和 CD8+ T 细胞浸润增加。因此,我们将 OPN 阻断与 cDC2 疫苗接种结合起来,通过结合抗血管生成和宿主免疫刺激效应,确定为未来治疗 CM 早期阶段的一种潜在干预措施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信